One concern regarding the administration of PTH[1–34] for the treatment of periprosthetic osteolysis is that it may enhance the risk of osteosarcoma, a malignant tumor that mostly occurs in adolescents and growing young adults. This evidence concerns the gene PTH and osteosarcoma.